How much muscle did Congress invest in a pair of bills recently signed by President Biden? The answer may lie in your willingness to believe.
Two much-touted bills for biologics and biosimilar advancement went to President Joe Biden’s desk for signing recently and were approved, but the devil is in the details, and whether they are going to have a tangible effect on biosimilar access is debatable.
The legislation changes the language of the Federal Food, Drug, and Cosmetic Act and urges greater efforts by federal regulators to educate the public about biosimilars, often a lower-cost alternative to originator biologics. “The Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021 are a much-needed boost to help normalize use of biosimilars, just as generics were normalized years ago,” said Joseph Leach, MD, chief medical officer of the pharmacy benefit manager Prime Therapeutics, which has successfully pushed for greater biosimilar use among its prescription drug plan participants.
The language of the education bill states that “The Secretary,” presumably the FDA, will work to “advance education and awareness” of biologics and biosimilars among health care providers. This would involve the creation of education programs on prescribing biologics. The new law also provides that the government “may” maintain and operate a website to provide educational materials for health care providers, patients, and caregivers about biologics and biosimilars.
Education Potential
There’s potential in the education bill in that it states that education efforts “shall” be directed at providers, said Chris Betti, PhD, an intellectual property attorney with Morgan Lewis specializing in biologics litigation. However, the act is “largely symbolic” because the FDA established a Biosimilars Action Plan in 2018 and that included the goal to educate providers and the public about biosimilars.
In addition, the act is heavily reliant on patients’ willingness to independently search out information about biosimilars and fill in any gaps by themselves. Simply dangling a website out there for patients may not have the desired effect, Betti said.
The Ensuring Innovation Act has its roots in efforts to break through originator biologic patent barriers that may prevent biosimilar developers from bringing their drugs to market, but in its approved form it isn’t capable of advancing that mission, Betti said. Patent thickets—clusters of patents created to protect the exclusivity of originator biologics—are likely to prove immune to the Ensuring Innovation Act.
This law has more value when it comes to clearing patent obstacles that hinder the emergence of small-molecule chemical compounds, otherwise known as generics, Betti said. “In the legislative history of this particular bill, there was a lot of discussion back and forth about biologics and what can be done about patent thickets. This bill does nothing to address biosimilars. Rather, it’s very narrowly focused on small molecules,” he said.
Wording Change Is Not Enough
The legislation changes the language of the Federal Food, Drug, and Cosmetic Act so that the words “active ingredient” are replaced with “active moiety.” This restricts the additional patenting that can be done when an originator company builds up a core drug compound with new active ingredients. Compounds are not biologics, though, as biologics are developed from living organisms. “This change has no effect on the biosimilars market and no effect on the exclusivity that is already given to biologics,” Betti said.
Patent thickets have the power to block biosimilar market entry from multiple angles, and addressing this is “not something that can be addressed by a very simple piece of legislation such as this. Some pretty substantial changes to the Patent Act would be required,” he said.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.